Core Viewpoint - iRhythm Technologies, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its role as a leading digital health care company focused on disease detection, prediction, and prevention [1][2]. Company Overview - iRhythm Technologies, Inc. is recognized for creating trusted solutions that utilize wearable biosensors and cloud-based data analytics, combined with proprietary algorithms, to transform data from millions of heartbeats into clinically actionable information [3]. - The company's vision emphasizes improving patient care through better data, insights, and overall health outcomes [3]. Event Participation - The management of iRhythm is scheduled to present at the conference on January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time, with a live and archived webcast available on the investor website [2].

Company Overview - iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital health company specializing in wearable biosensors and cloud-based analytics for cardiac monitoring, integrating AI into arrhythmia detection and predictive diagnostics [4] Industry Outlook - Morgan Stanley raised its price target on iRhythm Technologies from $195 to $205, maintaining an Overweight rating, reflecting a positive outlook for the MedTech industry heading into 2026 [1] - The MedTech industry is seen as well-positioned due to major product cycles, a supportive hospital spending environment, and current valuations at trough levels [1] Recent Developments - On November 21, iRhythm presented new data at the joint Asia Pacific Heart Rhythm Society and Japan Heart Rhythm Society scientific sessions, showcasing a large-scale retrospective analysis of its Zio long-term continuous ECG monitoring (LTCM) system [2] - The study involved data from 408,470 US patients using the Zio LTCM service for up to 14 days, demonstrating consistent performance in Asian patients compared to non-Asian patients, despite lower baseline prevalence of conditions like atrial fibrillation, heart failure, and coronary artery disease [3] - Detection rates and repeat monitoring rates were similar across diverse populations, supporting the generalizability of Zio monitoring [3]

Summary of iRhythm Technologies FY Conference Call (December 04, 2025) Company Overview - **Company**: iRhythm Technologies (NasdaqGS: IRTC) - **Industry**: Life Science Diagnostics and Medical Devices - **Key Products**: - **Zio Monitor**: Long-term continuous cardiac monitoring device, capable of monitoring for 14 days and collecting an average of 1.5 million heartbeats [3][4] - **Zio AT**: Mobile cardiac telemetry product launched in 2019, providing near real-time monitoring [5] Market Insights - **Market Size**: 6.7 million ambulatory cardiac monitoring tests in the U.S. annually, with long-term continuous monitoring being the largest and fastest-growing segment [6] - **Market Growth**: Long-term continuous monitoring is growing at a high teens percentage year-over-year [6] - **Market Share**: iRhythm holds over 70% market share in long-term continuous monitoring and approximately 15% in mobile cardiac telemetry [5][30] Competitive Landscape - **Key Competitors**: Traditional Holter monitors and event monitors, which still account for 2 million tests annually [6] - **Differentiation**: iRhythm emphasizes clinical and operational superiority, with a focus on AI tools for data analysis and high physician agreement rates (99%) on reports generated [8][9] Regulatory Environment - **NCD and LCD**: iRhythm has a National Coverage Determination (NCD) that is 20 years old, with recent concerns regarding proposed Local Coverage Determinations (LCDs) that may affect service level requirements [10][11] - **Industry Support**: The Heart Rhythm Society and other industry partners have provided feedback supporting iRhythm's position on the differentiation between long-term continuous monitoring and mobile cardiac telemetry [14] Financial Performance - **Revenue Growth**: Fiscal 2025 saw a revenue acceleration of 500 basis points over fiscal 2024, with growth attributed to the success of Zio AT, innovative channels, and EHR integration [18][19] - **Future Guidance**: Preliminary outlook for fiscal 2026 is 16%-18% growth, reflecting a step down from the previous year's performance due to difficult comparisons [65][66] Product Development - **Next-Gen MCT**: A new mobile cardiac telemetry product is in development, expected to extend monitoring to 21 days, which is anticipated to enhance market share [30][32] - **FDA Submission**: A traditional 510(k) submission was made for the new product, with ongoing discussions with the FDA regarding cybersecurity [32][34] Innovative Channels - **Strategy**: Focus on proactive monitoring for patients at risk of undiagnosed arrhythmias, with a target market of 27 million patients [46] - **Partnerships**: Currently working with 18 partners, with plans to expand to 40, emphasizing the importance of data-driven decision-making in identifying at-risk patients [45][51] EHR Integration - **Volume Uplift**: Accounts with EHR integration have seen a 25% increase in volume, with over 50% of orders now processed through EHR systems [58][61] - **Integration Benefits**: Streamlined workflows for clinicians, allowing for more efficient patient monitoring and report generation [58][60] Margin and Profitability - **Gross Margin Targets**: Long-term gross margin target of 72%-73% by 2027, with expectations for initial neutrality in margins from the new MCT product [40][41] - **EBITDA Expansion**: Aiming for 300-400 basis points of EBITDA expansion annually, with a target of 15% adjusted EBITDA by 2027 [68] Conclusion - **Overall Outlook**: iRhythm Technologies is positioned for continued growth in the cardiac monitoring market, with strong product offerings, a focus on innovation, and strategic partnerships aimed at capturing a larger share of the market while maintaining profitability [19][68]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - The company reported over 30% growth in the most recent quarter, indicating strong performance and momentum in the business [66] - Preliminary revenue guidance for 2026 is projected in the high teens, reflecting a thoughtful approach to setting expectations [65][66] Business Line Data and Key Metrics Changes - The long-term continuous monitoring segment, which the company pioneered, is growing at high teens percent year-over-year, outpacing the overall market growth [9][10] - The company has gained one to two points of market share in the long-term continuous monitoring segment, now holding a low 70% share of that market [19][20] Market Data and Key Metrics Changes - The overall ambulatory cardiac monitoring market in the U.S. is estimated at 6.7 million tests, growing at mid-single digits, while the long-term continuous monitoring segment is experiencing faster growth [8][9] - The aging population is a significant tailwind for the market, increasing the risk of cardiac arrhythmias and the need for monitoring [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the primary care market, with a goal to increase the percentage of XT patches used by primary care physicians from 30% to potentially over 40% [12][14] - The company is investing in innovative channel partnerships that allow for proactive monitoring of patients, which is expected to enhance market penetration [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's positioning to capitalize on market opportunities, particularly with the increasing awareness of cardiac arrhythmias and advancements in therapies [10][11] - The company is committed to maintaining profitable growth while investing in innovation, aiming for a 400 basis points expansion in adjusted EBITDA year-over-year [64] Other Important Information - The company is actively working on international expansion, having launched into five new markets, including Japan, which presents a significant opportunity for growth [54][55] - The company is addressing FDA comments regarding cybersecurity as part of the review process for Zio MCT, with no expected contribution to 2026 revenue [41][42] Q&A Session Summary Question: What is driving the accelerated growth in the ambulatory cardiac monitoring market? - Management highlighted several factors, including the shift to primary care, increased consumer awareness, and the aging population as key drivers of growth [10][11] Question: How is the company leveraging its channel partners? - The company has seen success with 18 active channel partners, with all pilot programs transitioning to full commercial programs, indicating strong value propositions [34][35] Question: What is the status of the FDA submission for Zio MCT? - The company received comments from the FDA and is working through the review process, with no expected revenue contribution from Zio MCT in 2026 [41][42] Question: Can you provide an update on the international business? - The company is making progress in international markets, particularly in Japan, and expects to see meaningful contributions starting in 2027 [54][55] Question: What are the reimbursement updates for the monitoring services? - Medicare rates for long-term continuous monitoring are expected to increase by approximately 8% next year, while rates for MCT may see a slight decrease [76]

Financial Data and Key Metrics Changes - The company reported over 30% growth in the most recent quarter, indicating strong performance and momentum in the business [66][67] - Preliminary revenue guidance for 2026 is projected in the high teens percentage range, reflecting a thoughtful approach to setting expectations [65][66] Business Line Data and Key Metrics Changes - The long-term continuous monitoring segment, which the company pioneered, is growing at high teens percentage year over year, outpacing the overall market growth [8][19] - The company has gained one to two points of market share in the long-term continuous monitoring segment, now holding approximately 70% of that market [19][20] Market Data and Key Metrics Changes - The overall ambulatory cardiac monitoring market in the U.S. is estimated at 6.7 million tests annually, growing at mid-single digits, while the long-term continuous monitoring segment is experiencing faster growth [8][10] - The aging population is a significant tailwind for the market, with more individuals entering Medicare and increasing the risk of cardiac arrhythmias [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the primary care market, with a goal to increase the percentage of XT patches used by primary care physicians from 30% to potentially over 40% [12][14] - The company is investing in innovative channel partnerships that allow for proactive monitoring of patients, which is expected to enhance market penetration [22][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on market opportunities, particularly in the context of improving therapies and increasing consumer awareness [10][11] - The company is optimistic about its international expansion efforts, having launched into five new markets, including Japan, and expects meaningful contributions from these markets in the future [55][56] Other Important Information - The company is currently working through the FDA review process for Zio MCT, with no expected contributions to revenue in 2026 [40][41] - Recent updates indicate that Medicare reimbursement rates for long-term continuous monitoring will increase by approximately 8% next year, which is a positive outcome for the company [76] Q&A Session Summary Question: What is the current state of the ambulatory cardiac monitoring market? - The market is healthy, with the long-term continuous monitoring segment growing at high teens percentage year over year, driven by factors such as improved therapies and increased consumer awareness [8][10] Question: How is the company addressing the primary care market? - The company has seen an increase in the percentage of XT patches used by primary care physicians and believes this trend will continue to expand [12][14] Question: What is the status of the FDA submission for Zio MCT? - The company submitted Zio MCT to the FDA in September and is currently addressing comments received, with no expected revenue contribution in 2026 [40][41] Question: How is the international business progressing? - The company has launched into five new markets and is optimistic about future contributions, particularly from Japan, which is a significant market for ambulatory cardiac monitoring [55][56] Question: What is the company's approach to setting revenue guidance? - The company aims to provide thoughtful guidance based on high confidence in certain areas while leaving out less predictable factors [66][67]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC), urging shareholders to take action promptly due to possible limited time to enforce their rights [1]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of iRhythm may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [2]. Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies, practices, and oversight, which can lead to enhanced transparency, accountability, and ultimately, increased shareholder value [3]. Group 3: Firm's Background and Achievements - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Insights - iRhythm Technologies presented new data at the 18th Asia Pacific Heart Rhythm Society and Japanese Heart Rhythm Society Joint Scientific Session, highlighting the performance of its Zio long-term continuous ECG monitoring system in diverse patient populations [1][7]. Group 1: Study Overview - The study, led by Dr. Hiro Kawata, analyzed 408,470 U.S. patients monitored between 2018 and 2022, comparing device compliance, performance, and arrhythmia detection between Asian and non-Asian populations [2][5]. - The analysis aimed to determine if racial and cultural differences impact the effectiveness of ambulatory cardiac monitoring [3]. Group 2: Key Findings - The findings indicated no significant differences in wear time, analyzable time, or arrhythmia detection yield between Asian and non-Asian patients, supporting the reliability of the Zio system across diverse populations [5][6]. - Median wear time was 13.6 days for Asian patients compared to 13.0 days for non-Asian patients, while analyzable ECG duration was 12.9 days for Asians versus 12.2 days for non-Asians [8]. - The arrhythmia detection rates were comparable, with Asian patients showing a 14.0% detection rate for atrial fibrillation compared to 14.3% for non-Asians [8]. Group 3: Implications for Japan - As Japan's population ages, the demand for advanced cardiac monitoring is increasing, with approximately 1.6 million tests prescribed annually [9]. - iRhythm's Zio ECG system, which allows for up to 14 days of continuous monitoring, represents a significant advancement over traditional monitoring options in Japan [10]. - The company is collaborating with local investigators to expand evidence and support the adoption of the Zio system in Japanese clinical practice [11]. Group 4: Supporting Evidence - The analysis adds to the growing body of evidence supporting the Zio LTCM service, which has been validated in previous studies such as CAMELOT and AVALON [12]. - iRhythm has generated over 2 billion hours of curated heartbeat data and more than 12 million patient reports, reinforcing its commitment to improving cardiac arrhythmia detection and management [13].

iRhythm Technologies Conference Summary Company Overview - **Company**: iRhythm Technologies (NasdaqGS: IRTC) - **Industry**: Digital healthcare focused on cardiac monitoring - **Event**: Jefferies London Healthcare Conference, November 20, 2025 Key Points Product and Technology - iRhythm's Zio platform combines hardware, software, and services for cardiac monitoring [2][4] - The Zio Monitor is a patented wearable biosensor that can be worn for up to 14 days, capturing an average of 1.5 million heartbeats [3][4] - The company has developed a second-generation FDA-cleared deep-learning algorithm, with a third generation in development [4] Financial Performance - Reported revenue for Q3 was $192.9 million, representing a year-over-year growth of 30.7% [5][23] - The company serves over 2 million patients annually and has a 30% share in its core market [5] - Guidance for full-year revenue is between $735 million and $740 million, indicating a 24-25% year-over-year growth [24] Market Opportunity - iRhythm identifies a total addressable market (TAM) of 27 million patients who are candidates for Zio monitoring [5][12] - The U.S. market for long-term continuous monitoring is approximately 3 million tests, where iRhythm holds over 70% market share [9] - Internationally, the company is targeting 5 million tests in prioritized countries, including the U.K., Japan, and several Western European nations [10][11] Clinical Evidence and Research - iRhythm has published 125 scientific manuscripts demonstrating the clinical and economic superiority of the Zio platform [6] - The company has a database of 2.5 billion hours of curated ECG data, enhancing the effectiveness of its AI tools [6] Strategic Initiatives - The company is pursuing a "Land and Expand" strategy to penetrate primary care markets [14][15] - EHR integration is a key focus, with over 50% of volume running through EHR systems, enhancing workflow efficiency [20][21] - iRhythm is developing a multivitals platform to gather additional patient data, targeting adjacent markets such as sleep monitoring [22][23] Financial Health and Future Outlook - Gross margin expanded to 71.1% in the most recent quarter, with a long-term target of 72-73% by 2027 [24] - Adjusted EBITDA margin was 11.2%, with a target of 15% by 2027 [24] - The company expects to be free cash flow positive for the first time in 2025, marking a significant milestone [25] Conclusion - iRhythm Technologies is well-positioned for sustainable growth, with significant market expansion opportunities and a strong focus on innovation and operational efficiency [26]

Summary of iRhythm Technologies Conference Call Company Overview - **Company**: iRhythm Technologies (NasdaqGS: IRTC) - **Industry**: Medical Devices, specifically focused on ambulatory cardiac monitoring Key Points and Arguments Industry Concerns - Recent concerns regarding Medicare Administrative Contractors (MACs) and their draft Local Coverage Decisions (LCDs) for ambulatory cardiac monitoring were addressed. The company reassured stakeholders that a national coverage decision supersedes local decisions, and they are confident in the process of public comments and industry feedback to ensure favorable outcomes [4][5][6][11]. Financial Performance - iRhythm's 2025 revenue guidance is projected to be 8% higher than the original midpoint, driven by strong performance across multiple channels, including XT monitors and AT products [13][14]. - The company has seen significant growth in the AT segment, with a notable competitive disruption benefiting their market position [14][24]. Market Dynamics - The rise of technologies such as pulse field ablation (PFA) and increased consumer awareness of atrial fibrillation (AFib) are contributing positively to iRhythm's performance. The company is well-positioned to capitalize on these market tailwinds [16][20]. - iRhythm holds over 70% market share in long-term continuous monitoring and approximately 15% in mobile cardiac telemetry (MCT), indicating substantial growth opportunities in the MCT segment [30][31]. Innovative Channel Partners (ICPs) - The company is focusing on innovative channel partners, which are value-based care entities that manage patient risk and have direct patient contact. This strategy is expected to enhance patient monitoring and diagnosis [32][33]. - The economic argument for proactive monitoring is strong, with potential cost savings of $15,000-$17,000 for hospital events compared to $250-$300 for home monitoring [35]. Future Outlook - iRhythm anticipates continued growth in 2026, with core business performance expected to remain strong. The company has not provided formal guidance but is comfortable with current market expectations [30][31]. - The next-generation MCT device is in the pipeline, with a 510(k) submission made in September. The company is cautious about timelines due to potential delays from the FDA [52][53]. International Market Challenges - International revenue is currently low, with challenges primarily related to securing premium reimbursement in markets like Japan. The company is conducting studies to support their reimbursement applications [67]. Operational Efficiency - The company has successfully executed its FDA remediation plan and is undergoing an independent audit of its quality management system, which is a priority for the organization [65][66]. Additional Important Insights - The company is seeing a demographic shift with over 4 million patients aging into Medicare annually, which could increase the demand for their monitoring services [45]. - iRhythm is developing algorithms to identify patients who may benefit from monitoring based on risk factors, enhancing their proactive monitoring capabilities [46]. This summary encapsulates the key discussions and insights from the iRhythm Technologies conference call, highlighting the company's strategic positioning, market dynamics, and future growth potential.